← All trials
NCT06919458
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 7, 2025
- Primary completion
- Apr 8, 2026
- Completion date
- Apr 8, 2026
- First posted
- Apr 9, 2025
- Last posted
- Apr 17, 2025
- Enrollment
- 146
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Asian Institute of GastroenterologyLead sponsor
- Postgraduate Institute of Medical Education and ResearchCollaborator
- Mahatma Gandhi Medical CollegeCollaborator
- Asian Institute of GastroenterologySponsor investigator
- Apollo Hospitals, Chennai, IndiaCollaborator
- Kalinga Institute of Medical Sciences, BhubaneswarCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.